P=N/A, N=23, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed

P4, N=90, Recruiting, Poznan University of Medical Sciences | Not yet recruiting --> Recruiting

P=N/A, N=180, Recruiting, Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo | Trial completion date: Jul 2024 --> Feb 2027 | Trial primary completion date: Apr 2024 --> Dec 2026

P3, N=970, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine | Initiation date: Jul 2025 --> Feb 2026

P2, N=140, Not yet recruiting, University of Nebraska

P=N/A, N=44, Active, not recruiting, College of Physicians and Surgeons Pakistan

In PROpel, there were no differences in HRQoL or pain scores reported by patients with mCRPC receiving olaparib + abiraterone versus placebo + abiraterone, suggesting that patients can derive a clinical benefit from olaparib + abiraterone while maintaining similar HRQoL in comparison with current standard-of-care treatment. The PROpel trial is registered on ClinicalTrials.gov as NCT03732820.

P=N/A, N=22, Completed, Ankara City Hospital Bilkent | Active, not recruiting --> Completed

TEL::AML1-positive patients demonstrated good prednisone responses (90%), with 90% 5-year OS...E2A::PBX1 and TEL::AML1 demonstrate favorable outcomes, whereas BCR::ABL, MLL::AF4 and SIL::TAL1 are associated with unfavorable prognosis. These findings provide valuable insights for risk stratification and treatment optimization in pediatric ALL.

P4, N=182, Not yet recruiting, Montefiore Medical Center

No significant difference was found on clinical features and prednisone response between groups at TP0-TP3 (all P>0.05)... Monitoring SIL::TAL1 fusion transcripts can reflect the clinical treatment response. The level of SIL::TAL1 fusion transcripts at early period can predict long-term outcomes of these patients.

A 71-year-old male with metastatic mucosal melanoma of the urethra was treated with immune checkpoint inhibitor (ICI) therapy (nivolumab/relatlimab) and developed vague epigastric discomfort...He was treated successfully with prednisone...Type 3 AIP typically presents along with other immune-related adverse events. Endoscopic ultrasound with FNB contributed to diagnostic certainty in this case and changed our patient's management, allowing for appropriate treatment of his immune-related adverse event.